Equity Details
Price & Market Data
Price: $0.97
Daily Change: +$0.035 / 3.61%
Daily Range: $0.90 - $1.00
Market Cap: $5,086,396
Daily Volume: 58,854
Performance Metrics
1 Week: -7.01%
1 Month: 12.91%
3 Months: -7.00%
6 Months: -9.71%
1 Year: -48.34%
YTD: -10.58%
About RedHill Biopharma Ltd. (RDHL)
An extensive look into RedHill Biopharma Ltd. (RDHL). Current price: 0.97, daily change: +$0.035 / 3.61%. Market cap: 5,086,396. Performance from YTD to 1-year.
Company Details
Employees: 13
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Israel
Details
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
